Pfizer yesterday asked the Food and Drug Administration to expand the emergency use authorization for its COVID-19 vaccine booster to include youth aged 16 and 17. 

“It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant,” tweeted Pfizer CEO Albert Bourla. 

FDA last month authorized, and the Centers for Disease Control and Prevention recommends (https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html), a single booster dose of the Pfizer or Moderna COVID-19 vaccine for all individuals aged 18 or older at least six months after receiving the initial two-dose series or two months after receiving the single-dose Johnson & Johnson vaccine. 
 

Related News Articles

Headline
A federal judge in Texas today dismissed the state’s challenge of the Centers for Medicare & Medicaid Services’ interim final rule requiring COVID-19…
Headline
The Centers for Medicare & Medicaid Services today released updated interpretive guidance on its Omnibus COVID-19 Health Care Staff Vaccination…
Blog
To help hospitals and health system leaders stay up-to-date on all of the legal developments related to vaccine mandates, the AHA has developed a blog…
Headline
Leaders from the AHA and the American College of Obstetricians and Gynecologists, hospital leaders, clinicians and experts from the Centers for Disease Control…
Headline
A new AHA video is tackling prominent myths about COVID-19 and its vaccines, providing the public with the facts they need to make sound health decisions…
Headline
In addition to the seven new 2022 ICD-10 procedure codes announced in November, the Centers for Medicare & Medicaid Services on April 1 will implement…